Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17001498 | 0.91 | ALDH1A1 (0.40) | ALDH1A1MEN1KMT2AMAPK1KDM4E | |
| SCHEMBL18268180 | 0.90 | CA2 (0.44) | ALDH1A1MEN1KMT2AMAPK1KDM4E | |
| SCHEMBL18270510 | 0.80 | KDM4E (0.43) | ALDH1A1MEN1KMT2AMAPK1KDM4E | |
| SCHEMBL18270538 | 0.80 | LMNA (0.42) | ALDH1A1MEN1KMT2AKDM4EHPGD | |
| SCHEMBL18270539 | 0.80 | LMNA (0.42) | ALDH1A1MEN1KMT2AKDM4EHPGD | |
| SCHEMBL18268186 | 0.78 | KDM4E (0.48) | ALDH1A1MEN1KMT2AMAPK1KDM4E | |
| SCHEMBL18268202 | 0.78 | KDM4E (0.48) | ALDH1A1MEN1KMT2AMAPK1KDM4E | |
| SCHEMBL18268188 | 0.78 | KDM4E (0.48) | ALDH1A1MEN1KMT2AMAPK1KDM4E | |
| SCHEMBL18268208 | 0.77 | KDM4E (0.41) | ALDH1A1MEN1KMT2AMAPK1KDM4E | |
| SCHEMBL18268181 | 0.75 | LMNA (0.38) | ALDH1A1MEN1KMT2AKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3102567-B1 | INHIBITORS OF PAXILLIN FUNCTION AND RELATED COMPOSITIONS AND METHODS | UNIV TENNESSEE RES FOUND (US) | 2019-07-17 | — | — | EP | disclosed |
| US-9834525-B2 | Inhibitors of paxillin function and related compositions and methods | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834525-B2 | Inhibitors of paxillin function and related compositions and methods | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160347725-A1 | INHIBITORS OF PAXILLIN FUNCTION AND RELATED COMPOSITIONS AND METHODS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2016-12-01 | — | — | US | disclosed |
| US-20160347725-A1 | INHIBITORS OF PAXILLIN FUNCTION AND RELATED COMPOSITIONS AND METHODS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2016-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347725-A1 | INHIBITORS OF PAXILLIN FUNCTION AND RELATED COMPOSITIONS AND METHODS | CTTN, PTK2, CDC42 | ALDH1A1 4856/4885MEN1 3157/4885KMT2A 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.